Scarica l'app Stockscreener
17.20
2.87%
-0.56
Precedente Chiudi:
$17.76
Aprire:
$17.45
Volume 24 ore:
1.05M
Relative Volume:
0.21
Capitalizzazione di mercato:
$1.85B
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-3.1387
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
+7.08%
1M Prestazione:
+51.58%
6M Prestazione:
+97.59%
1 anno Prestazione:
-16.65%
Intervallo 1D:
$16.72
$17.47
Intervallo di 1 settimana:
$14.80
$18.57
Portata 52W:
$5.90
$21.47
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
17.23 | 1.83B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.90 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.00 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.22 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
717.64 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
331.36 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com
Intellia Therapeutics (NASDAQ:NTLA) Shares Up 8%What's Next? - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Earns "Market Perform" Rating from JMP Securities - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at HC Wainwright - MarketBeat
Intellia to present data on CRISPR therapy for ATTR amyloidosis By Investing.com - Investing.com Nigeria
Voya Investment Management LLC Purchases 179,180 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Traders Purchase High Volume of Intellia Therapeutics Call Options (NASDAQ:NTLA) - MarketBeat
Intellia rises after completion of enrollment in angioedema study - MSN
Intellia to present data on CRISPR therapy for ATTR amyloidosis - Investing.com India
Global clinical trial of HAE gene-editing therapy now fully enrolled - Angioedema News
Cathie Wood's ARK Innovation ETF Expands Holdings in Intellia Th - GuruFocus
Intellia Therapeutics to Present Long-Term Data on Investigational Nex-z for ATTR Amyloidosis at International Conference in Italy - Quiver Quantitative
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times
Intellia Therapeutics to Present Longer-Term Data from the - GlobeNewswire
3 Years of Data: Intellia's Groundbreaking CRISPR Gene Therapy for Rare ATTR Disease Shows Long-term Results - Stock Titan
Energy Moves: Can Intellia Therapeutics Inc navigate macro headwinds2025 Trade Ideas & Reliable Momentum Entry Alerts - خودرو بانک
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpWhat's Next? - MarketBeat
Profit Review: Will Intellia Therapeutics Inc face regulatory challenges2025 Market WrapUp & Low Drawdown Momentum Ideas - خودرو بانک
Guidance Update: Will Intellia Therapeutics Inc. outperform tech stocksEarnings Performance Report & Long-Term Capital Growth Strategies - khodrobank.com
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME) - The Globe and Mail
Intellia Therapeutics (NASDAQ:NTLA) Shares Up 6.3%Time to Buy? - MarketBeat
Market Wrap: Can Intellia Therapeutics Inc stock double in the next yearSell Signal & Technical Confirmation Alerts - khodrobank.com
Is Intellia Therapeutics Inc in a consolidation phaseJuly 2025 Trends & Free High Return Stock Watch Alerts - خودرو بانک
Why Intellia ($NTLA) Just Had A Major Breakout - MSN
Intellia Therapeutics: Full Trial Enrollment Wows MarketUnderlines Buy Thesis (NTLA) - Seeking Alpha
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up - sharewise.com
Intellia Therapeutics stock price target raised to $30 from $25 at H.C. Wainwright - Investing.com India
NTLA: JMP Securities Reiterates Market Perform Rating | NTLA Stock News - GuruFocus
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details - MSN
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? - Yahoo Finance
NTLA: HC Wainwright & Co. Raises Price Target to $30 | NTLA Stoc - GuruFocus
H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock By Investing.com - Investing.com UK
Intellia Therapeutics Advances Lonvo-z Toward 2026 LaunchKeep This One On Your Watchlist - RTTNews
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Short Covering: What dividend growth rate does Intellia Therapeutics Inc offer2025 Market Sentiment & Growth Oriented Trade Recommendations - خودرو بانک
Aug EndMonth: Why is Intellia Therapeutics Inc stock going upTrade Volume Summary & Long-Term Safe Investment Ideas - khodrobank.com
Intellia stock rises after completing enrollment in Phase 3 HAE study By Investing.com - Investing.com South Africa
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback - Benzinga
Intellia Therapeutics Shares Are Ripping Higher: Here's Why - Benzinga
Earnings Update: Is Intellia Therapeutics Inc stock a hidden gemWeekly Trading Summary & Growth Focused Entry Reports - خودرو بانک
Intellia Therapeutics (NTLA) Surges 20% on Trial Enrollment Comp - GuruFocus
Intellia completes enrollment in phase 3 HAE gene therapy trial - Investing.com India
Aug Catalysts: Can Intellia Therapeutics Inc sustain its profitabilityJuly 2025 Summary & High Return Trade Guides - khodrobank.com
Retail Trends: Will Intellia Therapeutics Inc face regulatory challengesGlobal Markets & Trade Opportunity Analysis - خودرو بانک
Intellia stock rises after completing enrollment in Phase 3 HAE study - Investing.com
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Intellia completes enrollment in phase 3 HAE gene therapy trial By Investing.com - Investing.com Nigeria
Intellia Therapeutics Completes Enrollment in Phase 3 Study of Potential Hereditary Angioedema Treatment - MarketScreener
Intellia rises after enrolling patients in late-stage trial of genetic disorder drug - TradingView
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
0.23%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):